The Full Wiki

More info on Latanoprost

Latanoprost: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Systematic (IUPAC) name
isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2- [(3R)3-hydroxy-5-phenylpentyl]-cyclopentyl] hept-5-enoate
CAS number 130209-82-4
ATC code S01EE01
PubChem 60798
DrugBank APRD01065
Chemical data
Formula C 26H40O5  
Mol. mass 432.593 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life 17 minutes
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes Topical (eye drops)

Latanoprost (pronounced la-TA-noe-prost) ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes (through the uvealsclearal tract).

It is also known by the brand name of Xalatan manufactured by Pfizer. Annual sales are approximately $1.6 billion. The patent for latanoprost expires in 2011.


Adverse reactions

Possible side effects:

  • May cause reddening of the eyes (hyperemia)
  • May cause blurred vision;
  • May cause eyelid redness;
  • May permanently darken eyelashes;
  • May cause eye discomfort;
  • May eventually cause permanent darkening of the iris to brown (heterochromia);
  • May cause a temporary burning sensation during use.
  • May cause thickening of the eyelashes.
  • Rarely, herpes simplex keratitis.
  • A single case report links latanoprost use to the progression of keratoconus.[1]

External links

  • Xalatan (manufacturer's website)
  • Hara T (2001). "Increased iris pigmentation after use of latanoprost in Japanese brown eyes". Nippon Ganka Gakkai Zasshi 105 (5): 314–21. PMID 11406947.  

See also



Latanoprost can be used as a single therapy and it reduced IOP 27 to 35 percent after 6 months treatment.

Got something to say? Make a comment.
Your name
Your email address